

Application No. 10/540,443

Reply to Office Communication Dated: January 25, 2008

Response Dated: March 7, 2008

## REMARKS

In an Office Communication dated January 25, 2008, the Examiner in charge of this application requested that Applicants submit a Statement Under 37 C.F.R. § 1.821(g), confirming that no new matter was added in the previous amendment.

Further, the Examiner asserts that the message sequences in Table 2 of the Specification are drawn to species of (L)-Tyr-(D)-Thr-(L)-Gly-(L)-Phe (L)-Leu and that support for the entire genus encompassing (L)-Tyr-(D)-Xaa-(L)-Gly-(L)-Phe (L)-Leu could not be found in the disclosure as filed.

Without acquiescing or agreeing to the Examiner's objections, Applicants respond to the Office Communication by amending the Specification, Claims and Sequence Listing to delete references to SEQ ID NOs. for those amino acid sequences containing D-amino acids under 37 CFR 1.822(b). Also, Claims 1, 3, 4, and 7-10 are amended to clarify the structures of the glycosylated enkephalin peptides, such that the amino acid residue at position two of the peptide is a D-amino acid, namely D-Threonine. No new matter is added. In view of these amendments, Applicants respectfully request reconsideration of the merits of this application and the issuance of a timely Notice of Allowance in this case.

### Sequence Listing

In accord with the requirements set forth in 37 C.F.R. § 1.821(d), Applicants amend paragraphs [00018], Tables 1 and 2, as well as the claims, to delete SEQ ID NOs. having D-amino acids. Likewise, Applicants enclose with this submission a TXT version and a PDF version of an updated Sequence Listing, which lacks sequences having D-amino acids. Applicants direct entry of the enclosed Sequence Listing into the Specification. In view of these amendments and the submission, Applicants respectfully request reconsideration of this objection.

Application No. 10/540,443

Reply to Office Communication Dated: January 25, 2008

Response Dated: March 7, 2008


Statement Under 37 C.F.R. §§ 1.821(f) and (g)

The undersigned, an attorney registered to practice before the US Patent and Trademark Office (USPTO) and representing the Applicants in the above-identified patent application, hereby states and affirms that the sequence listing information in the computer readable form (*i.e.*, the TXT file copy) is identical to the paper copy form (*i.e.*, the PDF file copy) of the Sequence Listing, and are therefore believed to be the same. In addition, the undersigned hereby states and affirms that this submission includes no new matter.

Fees

A petition for a one-month extension of time accompanies this response so that it will be deemed to have been timely filed. No other extension of time is believed due, but should any additional extension be due, in this or any subsequent response, please consider this to be a petition for the appropriate extension, and a request to charge the extension fee to Deposit Account No. 17-0055. No additional fees are believed due; however, if any fees are due, in this or any subsequent response, please charge Deposit Account 17-0055.

Respectfully submitted,

  
Sara D. Vinarov  
Reg. No. 48,524  
Attorney for Applicants  
QUARLES & BRADY LLP  
P O Box 2113  
Madison, WI 53701-2113

TEL 608/251-5000  
FAX 608/251-9166